8-KItem 5.02 · Officer/Director ChangeItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements

IDEXX filed Item 9.01 exhibits: a Letter Agreement and an Amended & Restated Change‑in‑Control Agreement…

Filed with the SEC on January 13, 2026 · Summarized by InvestorsBot

IDEXX filed Item 9.01 exhibits: a Letter Agreement and an Amended & Restated Change‑in‑Control Agreement with Michael (Mike) Erickson, PhD, dated Jan 12, 2026 — indicates executive retention/CIC protections. $IDXX 📝🔁 #CorporateGov #ExecComp

IDEXX filed a Jan 12, 2026 Letter Agreement with Jonathan (Jay) Mazelsky and a press release (Exhibit 99.1) dated Jan 13, 2026 — investors should review the exhibits for disclosure details. $IDXX 📢📄 #IDXX #InvestorNews

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from IDEXX LABORATORIES INC /DE

IDEXX ($IDXX) filed an 8‑K (Item 9.01) disclosing a Separation Agreement (Exhibit 10.1) between Nimrata…

8-K · March 26, 2026

IDEXX ($IDXX) and Nimrata Hunt, EVP Global Strategy & Commercial, agreed she’ll cease her role Apr 13,…

8-K · March 26, 2026

IDEXX ($IDXX): Director M.

8-K · February 13, 2026

IDEXX furnished a press release titled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2025…

8-K · February 2, 2026

IDEXX ($IDXX) announced financial results for the quarter and year ended Dec 31, 2025 on Feb 2, 2026.

8-K · February 2, 2026

IDEXX LABORATORIES filed a Form 8‑K (Item 7.01) on Jan 13, 2026 furnishing a press release as Exhibit 99.1…

8-K · January 13, 2026